Home›US Markets›M&A & Deals›Eli Lilly acquisition of AtaiBeckley boosts psychedeli…

Eli Lilly acquisition of AtaiBeckley boosts psychedelic drug push

Reported · Written up by our desk · M&A & Deals

CNBC Markets reports that Eli Lilly is buying psychedelic drug maker AtaiBeckley, an acquisition that extends Big Pharma's growing interest in a medication class long associated with stigma.

The deal also signals a broader shift toward using psychedelics to address mental health conditions, with the buyer positioning the assets within its drug development pipeline.

By bringing the target under a large pharma umbrella, the transaction highlights how companies are increasingly willing to develop and commercialize psychedelic therapies for mental health treatment pathways.

More like this

Sources